Jun Gong/patientpower.info
Jan 28, 2025, 10:38
Jun Gong: Randomized Phase II trial of HB1801 at ASCO GI25
Jun Gong, Medical Oncologist and Researcher at Cedars-Sinai Medical Center, posted on X:
“Rand PhII trial of HB1801 (albumin-bound taxotere) vs taxotere in adv G/GEJ adenocarcinoma after at least 1L platinum-based chemo numerical but no significant difference in PFS at ASCO GI25.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 18, 2025, 20:22
Apr 18, 2025, 20:12
Apr 18, 2025, 20:03
Apr 18, 2025, 19:54
Apr 18, 2025, 19:49
Apr 18, 2025, 19:44
Apr 18, 2025, 19:26